203 related articles for article (PubMed ID: 19043439)
1. End of the line for cannabinoid receptor 1 as an anti-obesity target?
Jones D
Nat Rev Drug Discov; 2008 Dec; 7(12):961-2. PubMed ID: 19043439
[TBL] [Abstract][Full Text] [Related]
2. Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies.
Ward SJ; Raffa RB
Obesity (Silver Spring); 2011 Jul; 19(7):1325-34. PubMed ID: 21475141
[No Abstract] [Full Text] [Related]
3. [Rimonabant (Acomplia)].
Duh D; Vanddevijver A
J Pharm Belg; 2008 Mar; 63(1):27-8. PubMed ID: 18479080
[No Abstract] [Full Text] [Related]
4. Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks.
Gadde KM; Allison DB
Circulation; 2006 Aug; 114(9):974-84. PubMed ID: 16940206
[No Abstract] [Full Text] [Related]
5. Long term cannabinoid receptor (CB1) blockade in obesity: implications for the development of colorectal cancer.
Wright KL; Robertson DA; Moyer MP; Ward SG
Int J Cancer; 2008 Apr; 122(8):1920-1. PubMed ID: 18076045
[No Abstract] [Full Text] [Related]
6. Play an ADAGIO with a STRADIVARIUS: the right patient for CB1 receptor antagonists?
Di Marzo V
Nat Clin Pract Cardiovasc Med; 2008 Oct; 5(10):610-2. PubMed ID: 18695695
[No Abstract] [Full Text] [Related]
7. Cannabinoids and cardiovascular disease: the outlook for clinical treatments.
Ashton JC; Smith PF
Curr Vasc Pharmacol; 2007 Jul; 5(3):175-85. PubMed ID: 17627561
[TBL] [Abstract][Full Text] [Related]
8. Obesity drug development - CBI's 2nd Annual Summit.
Heal DJ
IDrugs; 2006 Oct; 9(10):682-5. PubMed ID: 17016771
[No Abstract] [Full Text] [Related]
9. The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism--or inverse agonism--as potential obesity treatment and other therapeutic use.
Xie S; Furjanic MA; Ferrara JJ; McAndrew NR; Ardino EL; Ngondara A; Bernstein Y; Thomas KJ; Kim E; Walker JM; Nagar S; Ward SJ; Raffa RB
J Clin Pharm Ther; 2007 Jun; 32(3):209-31. PubMed ID: 17489873
[TBL] [Abstract][Full Text] [Related]
10. [Sleep disorders associated with treatment with rimonabant].
Sempere AP; Giner-Bernabeu JC; Berenguer-Ruiz L; Selles-Galiana MF; Hernandez-Rubio L; Lezcano-Rodas M
Rev Neurol; 2008 Oct 16-31; 47(8):446. PubMed ID: 18937208
[No Abstract] [Full Text] [Related]
11. Rimonabant and progression of atherosclerosis in obese persons.
Dora JM; Scheffel RS
JAMA; 2008 Jul; 300(3):280; author reply 280-1. PubMed ID: 18632538
[No Abstract] [Full Text] [Related]
12. Rimonabant, obesity and diabetes.
Prescrire Int; 2007 Jun; 16(89):122. PubMed ID: 17585427
[TBL] [Abstract][Full Text] [Related]
13. Antagonism of type-1 cannabinoid receptors: good for obesity, but is it safe for fertility?
Maccarrone M; Wang H; Dey SK
Clin Endocrinol (Oxf); 2007 Mar; 66(3):456-7. PubMed ID: 17302885
[No Abstract] [Full Text] [Related]
14. [Pharmacology of cannabinoid receptors].
Le Fur G; Rinaldi-Carmona M; Barth F; Alexander J
Bull Acad Natl Med; 2007; 191(4-5):933-8; discussion 938-40. PubMed ID: 18225447
[TBL] [Abstract][Full Text] [Related]
15. ADAGIO-Lipids gives promises but faces the setbacks.
Taskinen MR
Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):339-40. PubMed ID: 19228609
[No Abstract] [Full Text] [Related]
16. Is the cannabinoid CB1 receptor antagonist rimonabant advancing the treatment of obesity?
Doggrell SA
Expert Opin Pharmacother; 2005 Oct; 6(12):2141-4. PubMed ID: 16197364
[No Abstract] [Full Text] [Related]
17. Effect of rimonabant on weight and cardiometabolic risk factors.
Gadde KM
JAMA; 2006 Aug; 296(6):649-50; author reply 650-1. PubMed ID: 16896103
[No Abstract] [Full Text] [Related]
18. [The endocannabinoid system and treatment of obesity].
Aronsen L
Tidsskr Nor Laegeforen; 2008 Feb; 128(5):570-1. PubMed ID: 18311201
[TBL] [Abstract][Full Text] [Related]
19. CB1 antagonists for obesity--what lessons have we learned from rimonabant?
Di Marzo V; Després JP
Nat Rev Endocrinol; 2009 Nov; 5(11):633-8. PubMed ID: 19844251
[TBL] [Abstract][Full Text] [Related]
20. Rimonabant induces partial seizures in a patient with a history of generalized epilepsy.
Braakman HM; van Oostenbrugge RJ; van Kranen-Mastenbroek VH; de Krom MC
Epilepsia; 2009 Sep; 50(9):2171-2. PubMed ID: 19706063
[No Abstract] [Full Text] [Related]
[Next] [New Search]
